Trial Profile
A Multicentre Open-label Phase II Study of Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Ixazomib (Primary) ; Methylprednisolone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms IDARA
- 31 Jan 2024 Last checked against European Clinical Trials Database record.
- 26 Jan 2024 This trail has been discontinued in France (End Date: 19 Dec 2023), according to European Clinical Trials Database record.
- 15 Jun 2023 Updated results evaluating efficacy and tolerability of Ixazomib and Daratumumab without Dexamethasone in elderly frail patients with relapsed myeloma , presented at the 28th Congress of the European Haematology Association